<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05119257</url>
  </required_header>
  <id_info>
    <org_study_id>InHeAb01</org_study_id>
    <nct_id>NCT05119257</nct_id>
  </id_info>
  <brief_title>(Bispecific) Antibodies in Cancer Patients</brief_title>
  <acronym>InHeAb01</acronym>
  <official_title>(Bispecific) Antibodies in Cancer Patients (InHeAb01)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <brief_summary>
    <textblock>
      The aim of this project is to provide (bispecific) antibodies to individual patients with&#xD;
      advanced solid and hematological malignancies without any available approved treatment&#xD;
      options.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ethics: Patient treatment will be conducted according to ยง13 Absatz 2b, AMG (German law).&#xD;
&#xD;
      All (bispecific antibodies) applied are developed and manufactured by the principle&#xD;
      investigator Prof. Helmut Salih.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
  </expanded_access_info>
  <condition>Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bispecific antibodies (bsAB)</intervention_name>
    <description>BsAbs equipped with a target-specificity directed to a TAA and an effector-specificity for an activating receptor on T cells, such as CD3 or CD28, are applied intravenously in repeated cycles until disease progression or dose limiting toxicity.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented diagnosis of advanced malignant disease&#xD;
&#xD;
          -  Advanced malignant disease without any available standard of care treatment option&#xD;
&#xD;
          -  Live expectancy &gt; 3 month&#xD;
&#xD;
          -  Ability to understand and voluntarily sign an informed consent form.&#xD;
&#xD;
          -  Ability to adhere to the visit schedule and other protocol requirements&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status score of โค 2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating females.&#xD;
&#xD;
          -  Treatment regimens inducing severe T cell deficiencies&#xD;
&#xD;
          -  Treatment-related side effect from prior cancer treatment &gt; CTC grade 2 (CTCAE V5.0)&#xD;
&#xD;
          -  Participation in any clinical study or having taken any investigational therapy, which&#xD;
             would interfere with the studys primary and secondary end points within 2 weeks prior&#xD;
             to Ab treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Helmut R. Salih, Prof.</last_name>
    <phone>+497071/2983275</phone>
    <email>helmut.salih@med.uni-tuebingen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Helmut R Salih, Prof.</last_name>
      <phone>+49(0)707129</phone>
      <phone_ext>83275</phone_ext>
      <email>helmut.salih@med.uni-tueningen.de</email>
    </contact>
    <contact_backup>
      <last_name>Juliane walz, Prof.</last_name>
      <phone>+49(0)707129</phone>
      <phone_ext>68746</phone_ext>
      <email>julian.walz@med.uni-tuebingen.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.medizin.uni-tuebingen.de/de/das-klinikum/einrichtungen/kliniken/medizinische-klinik/kke-translationale-immunologie</url>
    <description>CCU Translational Immunology</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 18, 2021</study_first_submitted>
  <study_first_submitted_qc>October 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2021</study_first_posted>
  <last_update_submitted>October 30, 2021</last_update_submitted>
  <last_update_submitted_qc>October 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Tuebingen</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Helmut Salih</investigator_full_name>
    <investigator_title>Head of CCU Translational Immunology (Developer and Manufacturer of applied bispecific antibodies)</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Bispecific</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

